BR112012018765A2 - agente profilático ou terapêutico para as doenças do trato biliar - Google Patents

agente profilático ou terapêutico para as doenças do trato biliar

Info

Publication number
BR112012018765A2
BR112012018765A2 BR112012018765A BR112012018765A BR112012018765A2 BR 112012018765 A2 BR112012018765 A2 BR 112012018765A2 BR 112012018765 A BR112012018765 A BR 112012018765A BR 112012018765 A BR112012018765 A BR 112012018765A BR 112012018765 A2 BR112012018765 A2 BR 112012018765A2
Authority
BR
Brazil
Prior art keywords
biliary tract
tract diseases
prophylactic
therapeutic agent
present
Prior art date
Application number
BR112012018765A
Other languages
English (en)
Other versions
BR112012018765B1 (pt
Inventor
Kaoru Nakao
Ryosuke Kobayashi
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BR112012018765A2 publication Critical patent/BR112012018765A2/pt
Publication of BR112012018765B1 publication Critical patent/BR112012018765B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

agente profilático ou terapêutico para as doenças do trato biliar. a presente invenção refere-se a um novo fármaco que tem um excelente efeito terapêutico nas doenças do trato biliar e é útil para a terapia e/ou profilaxia de doenças do trato biliar. mais particularmente, a presente invenção fornece um agente profilático e terapâutico para as doenças do trato biliar, cujo agente compreende como um componente eficaz de um composto específico tendo uma estrutura de morfinano representado pelo composto 1, ou um sal de adição de ácido farmaceuticamente aceitável dos mesmos.
BR112012018765A 2010-01-29 2011-01-28 uso de um derivado de morfinano como agente profilático ou terapêutico em doenças do trato biliar BR112012018765B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010018730 2010-01-29
PCT/JP2011/051737 WO2011093441A1 (ja) 2010-01-29 2011-01-28 胆道疾患の治療又は予防剤

Publications (2)

Publication Number Publication Date
BR112012018765A2 true BR112012018765A2 (pt) 2016-05-03
BR112012018765B1 BR112012018765B1 (pt) 2019-09-03

Family

ID=44319422

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018765A BR112012018765B1 (pt) 2010-01-29 2011-01-28 uso de um derivado de morfinano como agente profilático ou terapêutico em doenças do trato biliar

Country Status (15)

Country Link
US (1) US10131672B2 (pt)
EP (1) EP2529739B1 (pt)
JP (1) JP5867081B2 (pt)
KR (1) KR101732042B1 (pt)
CN (1) CN102711759B (pt)
AU (1) AU2011211223B2 (pt)
BR (1) BR112012018765B1 (pt)
CA (1) CA2787323C (pt)
ES (1) ES2582628T3 (pt)
MX (1) MX362830B (pt)
MY (1) MY173491A (pt)
PL (1) PL2529739T3 (pt)
RU (1) RU2554857C2 (pt)
TW (1) TWI477505B (pt)
WO (1) WO2011093441A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2630150B1 (en) * 2010-10-19 2017-04-12 Memorial Sloan-Kettering Cancer Center 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
MX2013008749A (es) 2011-01-31 2013-10-17 Toray Industries Agente terapeutico o profilactico para caquexia.
EP4212532A3 (en) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynine analogs and uses thereof
CN106110220B (zh) * 2016-08-22 2020-01-07 陕西盘龙药业集团股份有限公司 一种治疗胆道疾病的中成药的制备工艺
EP3761982A4 (en) 2018-03-08 2021-12-15 Victoria Link Ltd TREATMENT OF DEMYELINIZATION DISEASES
EP3826635A4 (en) 2018-07-23 2022-04-27 Trevi Therapeutics, Inc. TREATMENT OF CHRONIC COUGH, DIFFICULT BREATHING AND DYSPNEA
WO2020205735A1 (en) * 2019-03-29 2020-10-08 Humanwell Pharmaceutical US Novel morphinans useful for treating medical disorders
IL309232A (en) 2021-06-14 2024-02-01 Scorpion Therapeutics Inc History of urea which can be used to treat cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946848A (en) * 1985-10-29 1990-08-07 Baker Cumins Dermatologicals, Inc. Method of treating pruritus with nalmefene and clonidine
DK0591275T3 (da) * 1991-06-24 1999-10-11 Zeneca Ltd Anvendelse af 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyklohexandion til behandling af tyrosinæmi samt farmaceutiske sammen
ES2121988T3 (es) 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
EP0657163B1 (en) 1993-06-30 1998-10-14 Toray Industries, Inc. Antitussive
DE69414085T2 (de) 1993-07-19 1999-03-18 Toray Industries Wirkstoff zum schutze von gehirnzellen
NZ287243A (en) * 1994-05-31 1997-12-19 Mallinckrodt Chemical Inc Process for production of nalbuphine form alpha-noroxymorphol
EP1327444B1 (en) 1996-11-25 2005-03-23 Toray Industries, Inc. Antipruritic agent
WO1999005146A1 (fr) 1997-07-25 1999-02-04 Toray Industries, Inc. Remedes contre l'hyponatremie
EP0974363B1 (en) 1997-09-02 2005-06-22 Toray Industries, Inc. Remedies for drug addiction
JP2000053572A (ja) * 1998-08-11 2000-02-22 Toray Ind Inc ＯＲＬ１（ｏｐｉｏｉｄ ｏｒｐｈａｎ）受容体拮抗薬
ES2308990T3 (es) 1999-08-24 2008-12-16 Toray Industries, Inc. Remedios para el dolor neuropatico y modelos animales de dolor neuropatico.
JP2001163784A (ja) 1999-12-06 2001-06-19 Toray Ind Inc 角膜または結膜用止痒剤
PT1380306E (pt) * 2001-03-30 2009-05-25 Toray Industries Medicamentos para psiconeurose
EP1402899A4 (en) 2001-05-08 2009-03-11 Toray Industries MEANS FOR THE TREATMENT OF SEPSIS
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
US6852713B2 (en) 2003-04-16 2005-02-08 Adolor Corporation Lactam derivatives and methods of their use
US6992193B2 (en) 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use
US7034051B2 (en) 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
US7160902B2 (en) 2003-11-14 2007-01-09 Adolor Corporation Amide derivatives and methods of their use
WO2006095836A1 (ja) 2005-03-10 2006-09-14 Toray Industries, Inc. 多発性硬化症に伴う痒みに対する止痒剤
CA2685126C (en) * 2007-04-24 2015-04-14 Toray Industries, Inc. Therapeutic or prophylactic agent for dyskinesia
AU2008268202B2 (en) 2007-06-22 2012-12-20 Toray Industries, Inc. Remedy or preventive for integration dysfunction syndrome
BRPI0817804A8 (pt) * 2007-10-05 2017-04-18 Toray Industries Agente terapêutico para melhorar as propriedades da pele compreendendo um derivado de morfinano ou qualquer um de seus sais de adição de ácido farmacologicamente permissíveis como um ingrediente ativo
EP2252150B1 (en) * 2008-02-14 2018-04-11 Alkermes, Inc. Selective opioid compounds
WO2009132313A2 (en) * 2008-04-25 2009-10-29 Progenics Pharmaceuticals, Inc. Morphinan derivatives of organic and inorganic acids

Also Published As

Publication number Publication date
RU2012136826A (ru) 2014-03-10
MY173491A (en) 2020-01-29
JPWO2011093441A1 (ja) 2013-06-06
EP2529739A1 (en) 2012-12-05
CA2787323A1 (en) 2011-08-04
US10131672B2 (en) 2018-11-20
ES2582628T3 (es) 2016-09-14
EP2529739A4 (en) 2015-03-11
AU2011211223A1 (en) 2012-09-20
CN102711759A (zh) 2012-10-03
MX362830B (es) 2019-02-14
WO2011093441A1 (ja) 2011-08-04
US20130203797A1 (en) 2013-08-08
KR101732042B1 (ko) 2017-05-02
MX2012008509A (es) 2012-08-31
PL2529739T3 (pl) 2016-12-30
RU2554857C2 (ru) 2015-06-27
TWI477505B (zh) 2015-03-21
JP5867081B2 (ja) 2016-02-24
CN102711759B (zh) 2015-05-13
KR20120139713A (ko) 2012-12-27
TW201200521A (en) 2012-01-01
BR112012018765B1 (pt) 2019-09-03
EP2529739B1 (en) 2016-07-13
AU2011211223B2 (en) 2014-10-23
CA2787323C (en) 2017-08-29

Similar Documents

Publication Publication Date Title
BR112012018765A2 (pt) agente profilático ou terapêutico para as doenças do trato biliar
PH12015501404B1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
BR112015020302A2 (pt) derivado de pirazol
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
BR112015019921A2 (pt) composto inibidor de trk
BRPI0610321B8 (pt) imidazoquinolinas como inibidores de lipídeo cinase, seu uso e seu processo de preparação, e preparação farmacêutica
BR112012030810A2 (pt) "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
BR112012004851B8 (pt) uso de um derivado de tiazol
BR112015018491A2 (pt) triterpenoides c-19-modificados com atividade inibidora de maturação de hiv
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112013017302A2 (pt) formulações de imunossupressor
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112014016472A8 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112012015084A2 (pt) composição farmacêutica de liberação lenta de iloperidone
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112014029597A2 (pt) compostos de cromano
BR112014012277A2 (pt) composição farmacêutica para tratamento de reações alérgicas
BR112015028075A2 (pt) derivado de glicinamida alfa-substituída
BR112012022944A2 (pt) agente terapêutico ou agente profilático

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/01/2011, OBSERVADAS AS CONDICOES LEGAIS